Document Detail

Utilization of the smoking cessation medicine varenicline: an intensive post-marketing study in New Zealand.
MedLine Citation:
PMID:  20602347     Owner:  NLM     Status:  MEDLINE    
PURPOSE: To examine the utilization of varenicline during the first year of marketing in New Zealand (NZ) and to examine how this compares with the dosing instructions recommended in the Champix product information.
METHODS: Dispensing records for all NZ patients prescribed varenicline were collected by the Intensive Medicines Monitoring Programme (IMMP) during the first year this medicine was available in this country. Analyses of these data included patient characteristics and patterns of usage-in particular the duration of treatment dispensed as the first course. An assessment of the effectiveness of varenicline in post-marketing use was also performed on a sub-group of the cohort for whom follow-up information was available.
RESULTS: Of 3415 patients in the first year IMMP cohort, only 125 patients (4%) were dispensed the recommended 12 weeks varenicline treatment. 1299 (38%) were dispensed 14 days treatment (most often as a Starter Pack), 766 (22%) were dispensed 6 weeks, 411 (12%) were dispensed 4 weeks and 332 (8%) patients were dispensed more than 12 weeks treatment as a continuous course. The most common reasons for stopping varenicline prematurely were adverse reactions and cost of treatment. In a subgroup of 1299 patients, varenicline was reported to have been effective for 359 (28%) patients.
CONCLUSIONS: In 'real-life' post-marketing use, most patients did not receive 12 weeks varenicline treatment as recommended in the Champix product information. This observation may have implications for the effectiveness of this smoking cessation medicine.
Mira Harrison-Woolrych; Janelle Ashton
Related Documents :
8724337 - Computer aids to treatment in psychiatry.
19195847 - Long-term outcomes in patients with schizophrenia treated with risperidone long-acting ...
23677357 - Modern unicompartmental knee arthroplasty with cement: a concise follow-up, at a mean o...
23986617 - Comparing percutaneous primary and secondary biliary stenting for malignant biliary obs...
21831527 - A review on static splinting therapy to prevent burn scar contracture: do clinical and ...
17912217 - A new therapeutic strategy for the eradication of helicobacter pylori infection.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Pharmacoepidemiology and drug safety     Volume:  19     ISSN:  1099-1557     ISO Abbreviation:  Pharmacoepidemiol Drug Saf     Publication Date:  2010 Sep 
Date Detail:
Created Date:  2010-09-02     Completed Date:  2010-12-13     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9208369     Medline TA:  Pharmacoepidemiol Drug Saf     Country:  England    
Other Details:
Languages:  eng     Pagination:  949-53     Citation Subset:  IM    
Copyright Information:
(c) 2010 John Wiley & Sons, Ltd.
Intensive Medicines Monitoring Programme, Department of Preventive and Social Medicine, University of Otago, Dunedin, New Zealand.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Benzazepines / administration & dosage,  adverse effects,  therapeutic use*
Drug Costs
Drug Labeling
Drug Monitoring / methods
Follow-Up Studies
Middle Aged
New Zealand
Nicotinic Agonists / administration & dosage,  adverse effects,  therapeutic use*
Product Surveillance, Postmarketing
Quinoxalines / administration & dosage,  adverse effects,  therapeutic use*
Smoking Cessation / economics,  methods*
Time Factors
Young Adult
Reg. No./Substance:
0/Benzazepines; 0/Nicotinic Agonists; 0/Quinoxalines; 0/varenicline

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Automated data capture from free-text radiology reports to enhance accuracy of hospital inpatient st...
Next Document:  A solid-state approach to enable early development compounds: selection and animal bioavailability s...